Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 10/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052765 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL154357 | 0.89 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL425422 | 0.84 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15255033 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17479413 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL27552226 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30103795 | 0.81 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30450897 | 0.80 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL98410 | 0.79 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30514301 | 0.78 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206805-A1 | Combination Therapy with Gold Controlled Transgenes | CHIMERA BIOENGINEERING, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| CN-111989108-B | Coordinating gene expression using RNA destabilizing elements | 嵌合体生物工程公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4342978-A2 | GOLD OPTIMIZED CAR T-CELLS | Chimera Bioengineering Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3858365-B1 | GOLD OPTIMIZED CAR T-CELLS | CHIMERA BIOENGINEERING INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4232051-A1 | MERCURY CONTROLLED GENE EXPRESSION | CHIMERA BIOENGINEERING, INC. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11648277-B2 | Combination therapy with gold controlled transgenes | CHIMERA BIOENGINEERING, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11572566-B2 | Gold optimized CAR t-cells | CHIMERA BIOENGINEERING, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230028899-A1 | Mercury Controlled Gene Expression | CHIMERA BIOENGINEERING, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11535853-B2 | Gold optimized CAR T-cells | CHIMERA BIOENGINEERING, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11497774-B2 | Coordinating gene expression using RNA destabilizing elements | CHIMERA BIOENGINEERING, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220228156-A1 | Gold Optimized CAR T-cells | CHIMERA BIOENGINEERING, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220226381-A1 | Coordinating Gene Expression Using RNA Destabilizing Elements | CHIMERA BIOENGINEERING, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220204977-A1 | Gold Optimized CAR T-cells | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| EP-4013431-A1 | COMBINATION THERAPY WITH GOLD CONTROLLED TRANSGENES | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220186233-A1 | Gold Optimized CAR T-cells | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2022086875-A1 | MERCURY CONTROLLED GENE EXPRESSION | CHIMERA BIOENGINEERING, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11311577-B2 | Coordinating gene expression using RNA destabilizing elements | CHIMERA BIOENGINEERING, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| EP-1799273-A2 | USE OF THE STAUDINGER LIGATION IN IMAGING AND THERAPY END KITS FOR IMAGING AND THERAPY | Koninklijke Philips Electronics N.V. (NL) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038185-A2 | USE OF THE STAUDINGER LIGATION IN IMAGING AND THERAPY END KITS FOR IMAGING AND THERAPY | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | SLC28A1 4258/4885SLC28A2 4092/4885SLC29A1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.